ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.11
−0.92%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 15.57x
- Price / sales
- —
- Price / cash flow
- -57.48x
Enterprise value
- Enterprise value
- $5.4B
- EV / sales
- —
- EV / EBITDA
- -19.03x
- EV / EBIT
- -35.44x
- Market cap
- $5.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026